Wolters Kluwer Health to be Exclusive Provider of New England Journal of Medicine Site Licenses in China; Companies Expand Global Distribution Agreement

Wolters Kluwer Health today announced it has extended its global distribution agreement with the New England Journal of Medicine (NEJM.org),  the leading publisher of  breakthrough biomedical research and best practices in clinical medicine, to be the exclusive provider of NEJM site licenses in China. Under terms of the new agreement, Ovid, part of Wolters Kluwer Health, will be the exclusive provider of NEJM site licenses in China providing access to content upon publication on either Ovid or NEJM.org platforms as well as access to the NEJM archive on NEJM.org.

“China is an important growth market for NEJM and Wolters Kluwer Health brings extensive experience in this market to help us build our NEJM brand,” said Chris Lynch, VP for Publishing of NEJM Group. “The OvidSP research solution offers NEJM additional global reach, allowing us to bring important medical research and clinical content to even more healthcare professionals and researchers than ever before.”

“China is a fast growing market for medical research and our long standing presence and field sales force in this region offers tremendous advantage for partners like New England Journal of Medicine,” said Andrew Richardson, Vice President, Business Development, Wolters Kluwer Health, Medical Research. “We’re delighted to extend this partnership to bring highly valued content from NEJM to practitioners and students in China and around the world.”

In addition, Ovid will continue to provide access to current NEJM content to institutions globally through the Ovid platform. Ovid customers will have site-wide access to current issues of the New England Journal of Medicine back through 1990 in PDF format, plus links to NEJM’s Online First articles.

Ovid is a global information solutions provider offering clinicians, researchers, and students in the medical, scientific, and academic fields customizable solutions of trusted, evidence-based content, and tools and services that make research smarter, faster, and more effective. Ovid’s research platform is used by more than 12,500 institutions worldwide.